Myelodysplastic Syndromes

Myelodysplastic Syndromes (MSD) are a group of diseases in which the bone marrow does not make enough healthy blood cells. When there are fewer blood cells, there are higher chances of infection, anaemia, or internal bleeding.

In one of the studies, cord blood transplantation (CBT) done in 18 adult patients with Myelodysplastic Syndromes, fourteen of the patients are alive and free of disease at between 185 and 1332 days after transplantation. The probability of disease-free survival at 2 years was 76.6%. In another study, results from cord blood transplantation for 13 adult patients with advanced Myelodysplastic Syndromes suggest that adult advanced MSD patients should be considered as candidates for cord blood transplantation as it is effective with all treated patients having survived and free of disease.

Case Report

  • Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia

  • Unrelated cord blood transplantation for childhood acute myeloid leukemia: a Eurocord Group analysis

Clinical Trials

  • Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

  • Combination Chemotherapy Followed By Donor Umbilical Cord Blood Transplant in Treating Infants With High-Risk Acute Leukemia or Myelodysplastic Syndromes